Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial.
AIMS: The effect of beta-blockers initiated after myocardial infarction (MI) on subsequent angina burden remains uncertain. METHODS AND RESULTS: This pre-specified BETAMI-DANBLOCK substudy included patients with MI and left ventricular ejection fraction (LVEF)≥40% randomized to beta-blockers or no beta-blockers. Endpoints comprised angina-related hospital contacts/diagnostic ischemia tests, coronary revascularization, anti-anginal medications (≥2 prescriptions for calcium-channel blockers/nitrates), and patient-reported angina symptoms [Canadian Cardiovascular Society (CCS) class 0-4]. Subdistribution hazard ratios (SHR) were estimated by Fine-Gray models. Anti-anginal prescriptions were compared using 95% confidence intervals (CI) for differences in proportions.A total of 5574 patients were randomized to beta-blockers (n=2783, median dose 50 mg metoprolol) or no beta-blockers (n=2791). During median 3.5 years follow-up, an angina-related hospital contact/diagnostic ischemia test occurred in 724 patients (26.0%) in the beta-blocker group vs. 834 (29.9%) in the no beta-blocker group (SHR 0.85; 95% CI, 0.77-0.94). Coronary revascularization occurred in 108 (3.9%) vs. 110 patients (3.9%)(SHR 0.99; 95% CI 0.76-1.29). Fewer patients in the beta-blocker group were treated with calcium-channel blockers [630(22.7%) vs. 738(26.6%); -3.9 percentage points (95% CI, -6.2 to -1.6)], whereas nitrate use [342(12.3%) vs. 356(12.8%); -0.5 (95% CI, -2.2 to 1.2)] and CCS-scores were similar between groups (difference in change at 12-months, -0.04; 95% CI, -0.14-0.05). CONCLUSIONS: In patients with MI and LVEF≥40%, a moderate dose of beta-blockers was associated with a lower incidence of first angina-related hospital contact/diagnostic ischemia testing, and lower use of calcium-channel blockers. The absence of differences in coronary revascularization, nitrate use and patient-reported angina symptoms suggests that the overall benefit on angina is limited.
Authors
- Arnhild Bakken (ORCID: https://orcid.org/0009-0003-0338-1398)
- Therese Lucia Friis Holmager (ORCID: https://orcid.org/0000-0002-7667-7080)
- Morten Wang Fagerland (ORCID: https://orcid.org/0000-0003-4535-5043)
- Anna Meta Dyrvig Kristensen (ORCID: https://orcid.org/0000-0001-9608-7902)
- Michael Hecht Olsen (ORCID: https://orcid.org/0000-0003-2230-5780)
- Sigrun Halvorsen (ORCID: https://orcid.org/0000-0001-7561-7644)
- Dan Atar (ORCID: https://orcid.org/0000-0003-1513-8793)
- Eva Prescott (ORCID: https://orcid.org/0000-0002-4134-0349)
- John Munkhaugen (ORCID: https://orcid.org/0000-0001-6141-2162)
- F Rykind
Institutions
- University of Copenhagen (DK)
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Drammen Hospital (NO)
- Vestre Viken Hospital Trust (NO)
- Frederiksberg Hospital (DK)
- Bispebjerg Hospital (DK)
- Copenhagen University Hospital (DK)
- Holbæk Sygehus (DK)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/ehjcvp/pvag097
- Primary Topic
- Acute Myocardial Infarction Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00